ArticleDiscover oncology2025
Integrated machine learning and causal inference reveal CHRDL1 as a diagnostic and functional biomarker in NSCLC.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundNon-small cell lung cancer (NSCLC) accounts for the majority of lung cancer-related deaths, largely due to late diagnosis and limited early biomarkers. Integrating machine learning (ML) with causal inference may improve biomarker discovery and translational potential.
methodsSix NSCLC transcriptomic datasets were integrated and normalized. Differentially expressed genes were intersected with WGCNA modules to identify candidate features. A total of 114 ML models were constructed using various feature selection and classification algorithms, with model performance evaluated by area under the ROC curve (AUC). Immune cell infiltration was assessed using CIBERSORT. Causal relationships were evaluated via two-sample Mendelian randomization (MR) using pQTL and GWAS data. Functional pathways were explored using Gene Set Enrichment Analysis (GSEA) and Gene Set Variation Analysis (GSVA).
resultsA Random Forest model achieved the best performance (average AUC = 0.994) and identified nine diagnostic genes, including CHRDL1, FCN3, WIF1, MMP12, and AKR1B10. These genes showed strong diagnostic power (AUC > 0.80) and distinct immune-related expression patterns. MR analysis supported a causal protective role for CHRDL1 in NSCLC (IVW p = 0.0012), with no evidence of pleiotropy or heterogeneity. GSEA and GSVA revealed that high CHRDL1 expression was associated with immune activation, while low expression correlated with cell cycle progression.
conclusionThis integrative ML-MR framework identified CHRDL1 as a robust diagnostic and functionally relevant biomarker for NSCLC. These findings offer insights into the immune-proliferative landscape of NSCLC and provide a foundation for early detection and targeted therapy strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.